Want to see GUTS full AI Analyst Report?
GUTS Stock Chart & Stats
$0.57
-$0.12(-5.94%)
At close: 4:00 PM EST
$0.57
-$0.12(-5.94%)
Day’s Range― - ―
52-Week Range$0.38 - $2.45
Previous Close$1.96
Volume269.01K
Average Volume (3M)1.46M
Market Cap
$125.57M
Enterprise Value$59.01M
Total Cash (Recent Filing)$63.17M
Total Debt (Recent Filing)$60.82M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding158,648,960
10 Day Avg. Volume779,950
30 Day Avg. Volume1,463,761
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)17.64
Price to Sales (P/S)0.00
P/FCF Ratio-1.84
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$4.80Price Target Upside742.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial ExecutionCompleting a >300-patient, fully randomized pivotal with >90% retention materially lowers execution risk and supports robust statistical readouts. Durable trial execution enhances regulatory credibility, shortens regulatory review uncertainty, and strengthens future commercial positioning vs peers.
Regulatory & Reimbursement MomentumBreakthrough designation, favorable de novo feedback and potential CMS RAPID alignment create structural pathways to faster FDA review and earlier Medicare coverage. Securing CPT and transitional payments would materially improve hospital economics and long-term adoption prospects for a procedural therapy.
Pipeline Diversification: Rejuva Enters ClinicAdvancing RJVA-001 to first-in-human study creates a second clinical-stage asset, reducing single-program concentration. A successful AAV-based GLP-1 gene therapy would be transformational and provides multi-year upside independent of Revita, improving strategic optionality for product and partnership pathways.
Bears Say
High Cash BurnSustained negative operating and free cash flow at ~-$88M TTM is a structural constraint for a pre-revenue biotech. Persistent burn necessitates financing or sharp expense cuts, limiting runway for development programs and increasing the likelihood of dilution or constrained investment in commercialization capacity.
Limited Cash RunwayA stated runway into early 2027 with the ATM closed and no planned raise before pivotal data creates a durable financing overhang. Any trial delay or adverse result would force urgent capital raises under pressure, risking unfavorable terms, operational disruption, or scaled-back programs.
Elevated LeverageDebt materially exceeds equity for a pre-revenue company, leaving limited balance-sheet flexibility. Elevated leverage raises refinancing risk and could constrain strategic options, forcing priority on near-term milestones to avoid covenant issues or additional dilutive financing if clinical timelines slip.
Fractyl Health, Inc. News
GUTS FAQ
What was Fractyl Health, Inc.’s price range in the past 12 months?
Fractyl Health, Inc. lowest stock price was $0.38 and its highest was $2.44 in the past 12 months.
What is Fractyl Health, Inc.’s market cap?
Fractyl Health, Inc.’s market cap is $125.57M.
When is Fractyl Health, Inc.’s upcoming earnings report date?
Fractyl Health, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 38 days.
How were Fractyl Health, Inc.’s earnings last quarter?
Fractyl Health, Inc. released its earnings results on May 12, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.22.
Is Fractyl Health, Inc. overvalued?
According to Wall Street analysts Fractyl Health, Inc.’s price is currently Undervalued.
Does Fractyl Health, Inc. pay dividends?
Fractyl Health, Inc. does not currently pay dividends.
What is Fractyl Health, Inc.’s EPS estimate?
Fractyl Health, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Fractyl Health, Inc. have?
Fractyl Health, Inc. has 158,648,960 shares outstanding.
What happened to Fractyl Health, Inc.’s price movement after its last earnings report?
Fractyl Health, Inc. reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went up 29.155%.
Which hedge fund is a major shareholder of Fractyl Health, Inc.?
Currently, no hedge funds are holding shares in GUTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fractyl Health, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.80 (742.11% Upside)
$4.80 (742.11% Upside)
Blogger Sentiment
Bullish
GUTS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $108.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.30%
12-Months-Change
Fundamentals
Return on Equity
-4573.89%
Trailing 12-Months
Asset Growth
19.68%
Trailing 12-Months
Company Description
Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
GUTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong clinical execution, external validation, regulatory and reimbursement progress, and a clear catalyst timeline — all supportive of the company's strategic thesis. Financially, the company has reduced operating spend and improved adjusted EBITDA, but remains cash-limited with a runway into early 2027 and continues to report negative adjusted profitability. Several regulatory and operational uncertainties remain (RAPID implementation, full de novo approval, U.S. regulatory engagement for Rejuva) and the near-term plan is contingent on multiple upcoming clinical readouts. Overall, clinical and regulatory momentum and cost discipline are material positives, but the constrained cash runway and remaining execution/regulatory risks temper the outlook.View all GUTS earnings summariesGUTS Stock 12 Month Forecast
Average Price Target
$4.80
▲(742.11% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
―
Innate Pharma
―
Ownership Overview
6.64% Insiders
4.29% Mutual Funds
0.04% Other Institutional Investors
85.63% Public Companies and Individual Investors
Options Prices
Currently, No data available
---